GSK’s (GSK) “Buy” Rating Reiterated at Jefferies Financial Group

Jefferies Financial Group reaffirmed their buy rating on shares of GSK (LON:GSK) in a research report released on Thursday morning,London Stock Exchange reports. Jefferies Financial Group currently has a GBX 2,450 target price on the stock.

Other equities analysts have also recently issued reports about the company. UBS Group restated a “neutral” rating and set a GBX 1,940 target price on shares of GSK in a research report on Friday, January 23rd. Deutsche Bank Aktiengesellschaft lifted their price target on GSK from GBX 1,600 to GBX 1,675 and gave the company a “hold” rating in a research report on Thursday, January 15th. Berenberg Bank reissued a “hold” rating and set a GBX 2,000 price objective on shares of GSK in a report on Thursday, March 26th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of GSK in a report on Wednesday, January 7th. Finally, Citigroup boosted their target price on GSK from GBX 1,900 to GBX 2,250 and gave the stock a “buy” rating in a research report on Monday, February 9th. Three analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of GBX 2,016.43.

GSK Price Performance

Shares of GSK stock opened at GBX 2,144 on Thursday. The stock’s 50-day moving average is GBX 2,070.60 and its 200 day moving average is GBX 1,855.16. The company has a debt-to-equity ratio of 108.20, a current ratio of 0.82 and a quick ratio of 0.73. The firm has a market cap of £86.00 billion, a price-to-earnings ratio of 15.45, a PEG ratio of 1.24 and a beta of 0.32. GSK has a one year low of GBX 1,242.50 and a one year high of GBX 2,282.

GSK (LON:GSK) last posted its earnings results on Wednesday, February 4th. The company reported GBX 172 earnings per share (EPS) for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. Equities research analysts anticipate that GSK will post 175.980975 EPS for the current year.

Insiders Place Their Bets

In other GSK news, insider Jonathan Symonds bought 5,000 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The stock was bought at an average price of GBX 1,951 per share, for a total transaction of £97,550. Also, insider Anne Beal bought 196 shares of the firm’s stock in a transaction that occurred on Friday, March 20th. The shares were acquired at an average price of GBX 5,179 per share, with a total value of £10,150.84. In the last quarter, insiders have acquired 11,447 shares of company stock worth $24,273,097. Corporate insiders own 0.26% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.